GLP-1 for Prediabetes

Prediabetes means glucose sitting above normal but below the line that would make it diabetes — fasting between 100 and 125 mg/dL, or an A1c of 5.7 to 6.4%. Roughly 98 million Americans are in that band, and left alone somewhere between 15 and 30% of them will cross into type 2 diabetes inside five years.

Nothing in this class is approved for prediabetes. Using one here is off-label and preventive: the aim is not to treat a disease you already have but to produce the sustained weight loss — 5 to 10% and upward — that reliably undoes insulin resistance and can push the diagnosis away or off the table entirely.

The case for weight loss as prevention is strong. These drugs take off consistently more than lifestyle change manages alone, and the large obesity trials keep showing high rates of people returning to normal glucose. The indication is still off-label, which in practice means prescribers document obesity or weight management as the basis when coverage is in play.

The benchmark predates all of this. The Diabetes Prevention Program found that intensive lifestyle change aimed at 5 to 7% weight loss cut new type 2 diabetes by 58% across roughly three years, among adults whose glucose tolerance was already impaired [1]. Since these drugs routinely exceed that weight target, the prevention argument follows fairly directly.

The largest dedicated study in this population ran three years. Liraglutide 3 mg against placebo significantly delayed the onset of type 2 diabetes and returned far more participants from prediabetes to normal glucose across the treatment period [2].

STEP-1 recorded a mean 14.9% weight reduction over 68 weeks in adults with excess weight and no diabetes — a population containing many people who met prediabetes criteria at entry [3]. Losses of that size line up with reversion to normal glucose in post-hoc analyses across the program.

Durability is the part that decides whether any of this matters. STEP-5 held 15.2% weight loss at two years against 2.6% on placebo [4]. Short-lived glucose improvements that unwind with regained weight protect nobody; losses sustained across years are what produce durable normal glucose.

SURMOUNT-1 enrolled a substantial number of participants who had prediabetes at baseline, and among them significantly more on tirzepatide had returned to normal glucose by week 72 than on placebo [6].

SELECT enrolled adults who had obesity and known heart disease but not diabetes, testing semaglutide 2.4 mg, cutting major adverse cardiac events by 20% over roughly 3.3 years [5]. That establishes cardiovascular benefit at weight-loss dosing without diabetes present — directly relevant, since a great many people with prediabetes are also carrying raised cardiovascular risk.

A 2026 review pulling together the semaglutide and tirzepatide evidence in this population concluded both produce clinically meaningful glycemic reversion and cardiovascular risk reduction, enough to support off-label preventive use in high-risk individuals — while noting the obvious gap, which is that dedicated randomized trials with diabetes prevention as the primary endpoint remain scarce [7].

As off-label prevention, the strongest case is someone who has not got far enough on lifestyle change alone and carries additional risk: a BMI over 30, a strong family history, metabolic syndrome, previous gestational diabetes, or an A1c drifting toward the top of the range at 6.2 to 6.4%.

Anyone who has prediabetes and also meets the obesity thresholds — BMI 30 or above, or 27 with a qualifying condition — can be prescribed Wegovy or Zepbound under the approved obesity indication instead. That is an on-label route to the same drug, with the glucose improvement arriving as a consequence of the weight loss rather than as the stated reason for treatment.

Prediabetes on its own, without obesity or another qualifying condition, is the hardest case: coverage is unlikely and the cost falls on you. Structured lifestyle intervention on the Diabetes Prevention Program model remains first-line here and genuinely works, particularly where an organized program is actually available rather than merely recommended.

Off-label status is mostly a reimbursement problem. Insurers and Medicare do not generally pay for these drugs against prediabetes; what gets covered, if anything, runs through the obesity indication and its BMI threshold. Settle that before writing the prescription rather than after.

Regain after stopping is the central limitation. Withdrawal data from STEP-1 showed weight coming back and glucose worsening within a year of stopping semaglutide. Long-term and possibly indefinite use is the realistic frame, and it belongs in the conversation before anyone starts rather than a year in.

Lifestyle work should run alongside whatever is prescribed. The Diabetes Prevention Program showed how effective it is on its own, and it remains far more accessible than any of these drugs; medication is best understood as something added on top, or fallen back on when those targets prove impossible to hold [1].

Prediabetes produces no symptoms, so it is found and followed by lab work. Anyone treated for it should have A1c and fasting glucose rechecked every six to twelve months, to establish whether normal glucose has been reached and held — or whether things are progressing regardless.

Stomach side effects are the usual tolerability issue and generally ease as the dose climbs slowly across four or five months. The class contraindication applies unchanged: not for anyone whose own or family history includes medullary thyroid carcinoma or multiple endocrine neoplasia type 2.